argenex SE $ARGX Stock Holdings Raised by UBS Group AG

Key Points

• UBS Group AG raised its stake in argenex by 12.3% in Q4 to 60,384 shares (about $50.78M), and institutional investors now own roughly 60.32% of the company.
• argenex reported $8.02 EPS for the quarter with a 30.42% net margin and 38.51% ROE, and analysts project about 24.63 EPS for the current fiscal year.
• The stock opened near $794.70 with a market cap of $49.4B, and carries a consensus rating of "Moderate Buy" with a consensus price target of $1,016.22.

UBS Group AG raised its stake in argenex SE (NASDAQ:ARGX - Free Report) by 12.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 60,384 shares of the company's stock after purchasing an additional 6,591 shares during the period. UBS Group AG owned 0.10% of argenex worth $50,780,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of ARGX. Abound Wealth Management increased its stake in argenex by 3,200.0% during the fourth quarter. Abound Wealth Management now owns 33 shares of the company's stock valued at $28,000 after purchasing an additional 32 shares during the last quarter. Sound Income Strategies LLC bought a new position in argenex during the 4th quarter worth $28,000. Ameriflex Group Inc. bought a new position in argenex during the 3rd quarter worth $32,000. Sunbelt Securities Inc. bought a new position in argenex during the 3rd quarter worth $36,000. Finally, Aventura Private Wealth LLC bought a new position in argenex during the 4th quarter worth $38,000. Institutional investors own 60.32% of the company's stock.

Get argenex SMS alerts:

Sign Up

argenex Stock Performance

Shares of NASDAQ:ARGX opened at $794.70 on Wednesday. The stock has a market capitalization of $49.42 billion, a price-to-earnings ratio of 40.71, a PEG ratio of 1.33 and a beta of 0.46. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The company has a 50 day moving average price of $757.32 and a 200 day moving average price of $818.15.

argenex (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Saturday, February 14th. The company reported $8.02 earnings per share for the quarter. argenex had a net margin of 30.42% and a return on equity of 38.51%. On average, sell-side analysts expect that argenex SE will post 24.63 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Robert W. Baird upped their price objective on argenex from $858.00 to $867.00 and gave the stock a "neutral" rating in a research note on Friday, February 27th. Truist Financial increased their price objective on argenex from $950.00 to $1,030.00 and gave the stock a "buy" rating in a report on Thursday, January 8th. Glj Research upgraded shares of argenex to a "strong-buy" rating in a report on Friday, April 3rd. Citigroup decreased their price target on argenex from $1,124.00 to $1,091.00 and set a "buy" rating for the company in a research note on Thursday, January 8th. Finally, Oppenheimer decreased their price target on argenex from $1,060.00 to $1,014.00 and set an "outperform" rating for the company in a research note on Thursday, April 2nd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, argenex currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,016.22.

argenex Profile

argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.